A dangerous duo: Heart disease and diabetes

October 01, 2003

The prevalence of obesity and diabetes is increasing worldwide and diabetes currently represents the leading cause of blindness, renal failure, and amputation in the USA. However, these conditions can be slowed or prevented by controlling glucose levels within the body. Interestingly, individuals with diabetes have a two to four-fold higher risk of developing heart disease. However, to date, scientists have been unable to determine how high levels of glucose lead to excess cardiovascular risk. Surprisingly, the treatment of hyperglycemia, exclusive of other heart disease intervention protocols, is currently inadequate to reverse or reduce heart disease. In the October 1 issue of the Journal of Clinical Investigation, a study by Michael A. Brownlee and colleagues from Albert Einstein College of Medicine in New York, reveals a new target - an enzyme called PARP - that is dysregulated by high glucose levels, resulting in increased oxidative stress, which effects endothelial cells lining the heart and blood vessels. The authors demonstrated that inhibition of PARP activation blocked all the known pathways of hyperglycemia-induced vascular damage, suggesting that PARP inhibitors might have unique clinical efficacy in preventing the development and progression of diabetic complications of the cardiovascular system.

In an accompanying commentary, Jane Reusch from the University of Colorado Health Sciences Center comments "with the incidence of diabetes and its complications on the rise, these results offer hope for new treatments in the foreseeable future".
-end-
TITLE: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells

AUTHOR CONTACT:
Michael A. Brownlee
Albert Einstein College of Medicine, New York, New York, USA.
Phone: 718-430-3636
Fax: 718-430-8570
Email: brownlee@aecom.yu.edu

View the PDF of this article at: http://www.jci.org/cgi/content/full/112/7/1049

ACCOMPANYING COMMENTARY:
Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?

AUTHOR CONTACT:
Jane E. B. Reusch
Veterans Affairs Medical Center, Denver, Colorado, USA.
Phone: 303-399-8020 ext. 2775
Fax: 303-393-5271
Email: jane.reusch@uchsc.edu

JCI Journals

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.